Is Exelixis, Inc. Stock a Bad News Buy?
Is the 75% drop in Exelixis, Inc. stock justified? Two of our top analysts weigh in and discuss the company's potential as a "bad news buy".
3 Biotech Stocks Near 52-Week Lows Worth Buying
These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.
Big News for These 5 Stocks From ESMO
But smaller biotechs Clovis Oncology and Exelixis also benefit from the big boys' data.
Why Exelixis, Inc. Stock Is Soaring Today
Shares of small-cap biopharma Exelixis Inc. are up big today. Here's why.